FDA Section 524B is the US medical device cybersecurity requirement that obliges certain device submissions to include security information and processes for addressing vulnerabilities. It pushes manufacturers to document cybersecurity design, software materials, update mechanisms, and coordinated vulnerability handling, so devices can be maintained safely after release.
What FDA Section 524B Requires in Practice
FDA Section 524B turns cybersecurity into a premarket submission issue for certain medical devices, not just a post-release operational concern. It requires manufacturers to describe the device’s security posture, how vulnerabilities will be managed, and how maintenance will continue after deployment.
For device makers, the practical shift is that cybersecurity evidence must be engineered into the product and its submission package. That usually means treating security architecture, software inventory, update pathways, and vulnerability handling as part of the device’s regulatory design story, not as an afterthought.
NHIMG’s Medical Device Security Guide is the most direct companion resource for understanding how FDA Section 524B fits into a wider medical device security programme.
Why the Requirement Exists
Medical devices can remain in service for years, often inside clinical environments where patch windows are limited and downtime is costly. Section 524B exists because a device that cannot be securely updated, monitored, or remediated becomes a long-lived exposure point once it is in the field.
The rule also reflects the reality that device risk is not limited to the product itself. A weak software component, unclear support model, or missing vulnerability process can affect hospital operations, patient safety, and the organisation’s ability to keep the device trustworthy over time.
That lifecycle view is why security materials such as software bills of materials, design documentation, and update governance matter. They help reviewers understand whether the manufacturer can support the product safely after release, and whether risk is manageable when vulnerabilities emerge.
What Organisations Need to Show
To assess exposure, organisations usually need a complete inventory of the device, its software components, and where it is deployed. They also need to know whether the device is internet-exposed, how it is segmented, and whether the vendor has issued cybersecurity guidance, advisories, or support commitments relevant to the exact model.
Submission readiness is not only about listing components. It is about demonstrating that the device can be maintained securely, that vulnerabilities can be received and triaged, and that software updates or mitigations can be delivered without breaking the intended clinical use.
This is why NIST Cybersecurity Framework 2.0 is useful as a broad organising lens, while the device-specific evidence comes from the manufacturer’s documentation and regulatory submission materials.
How Security Maintenance and Response Should Work
Section 524B is ultimately about whether the device can stay safe after release. A strong programme includes vulnerability intake, software maintenance processes, update validation, and clear responsibility for coordinated disclosure when a defect is reported.
When patching is delayed, compensating controls matter: network isolation, strict access limits, monitoring for unusual device behaviour, and clinical workarounds that preserve safety until a fix is available. The point is to reduce exposure without assuming every device can be updated immediately.
For the technical control layer, NIST SP 800-53 Rev 5 Security and Privacy Controls provides a useful control vocabulary for access control, integrity, auditability, and configuration management, while NIST Cybersecurity Framework 2.0 helps structure ongoing governance and recovery expectations.
Risk and Threat Considerations
Section 524B matters because medical devices can become durable attack surfaces if the manufacturer cannot describe, fix, or monitor security weaknesses after shipment. The biggest risks are exposed devices, unpatched software flaws, and fragmented responsibility between vendor, healthcare provider, and clinical operators.
Failure mechanism: An attacker or opportunistic scanner can exploit an externally reachable device, abuse a vulnerable component, or rely on delayed remediation to keep access available longer than defenders expect.
Impact: Compromise can lead to service disruption, unsafe device behaviour, loss of clinical availability, or a need for emergency isolation and replacement work that is expensive and operationally disruptive.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST CSF 2.0, NIST SP 800-53 Rev 5 and CIS Controls v8 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST CSF 2.0 | GV.OC-01 — Organizational Context | Section 524B sits within device security governance and lifecycle accountability. |
| GV.SC-01 — Cyber Supply Chain Risk Management Strategy | The rule requires vendor-controlled software, updates, and vulnerability handling. | |
| Recommendation — Define device cybersecurity obligations and ownership across the product lifecycle. Require supplier security evidence for components, updates, and vulnerability response. | ||
| NIST SP 800-53 Rev 5 | SA-11 — Developer Testing and Evaluation | Premarket cybersecurity evidence depends on testing and evaluation of device security features. |
| SI-2 — Flaw Remediation | Section 524B explicitly centers vulnerability handling and post-release maintenance. | |
| CM-8 — System Component Inventory | Device submissions need software and component visibility to support cybersecurity review. | |
| Recommendation — Verify device security controls through pre-release testing and evaluation. Establish flaw remediation processes for discovered device vulnerabilities. Maintain an accurate inventory of device software and related components. | ||
| CIS Controls v8 | CIS-16 — Application Software Security | Medical device software security and update handling align with secure software practices. |
| Recommendation — Build and maintain secure software practices for device code and updates. | ||
Practitioner Guidance
What to watch for: Treat missing software inventory, vague update commitments, and weak vulnerability disclosure language as warning signs during procurement and premarket review. Those gaps usually indicate that post-release maintenance may be difficult or slow.
Governance implication: Make cybersecurity maintenance evidence a required part of device acceptance, not a vendor reassurance. If the submission does not explain how vulnerabilities will be found, assessed, and handled over the device lifecycle, the security case is incomplete.
Practitioner takeaway: For Section 524B, the key question is not whether a device was designed securely once, but whether it can be kept secure throughout its real operating life.
Related resources from NHI Mgmt Group
- How should financial firms reduce standing privileged access for NYDFS Section 500.7?
- Why does just-in-time access matter under NYDFS Section 500.7?
- Who is accountable when automated triage informs FDA or SEC reporting?
- What breaks in practice when a malicious package assumes package.json already contains a scripts section?